Patented Data and Devices for Pharmaceutical Cannabis

For all of the talk about cannabis as a medicine and potential treatment for a wide variety of ailments, from sleep to stress to pain disorders and more, there is a huge missing element. There are almost no FDA-approved cannabis-derived medicines. The potential is very large considering the prevalence and market size of many of these conditions, so why aren’t we seeing more advanced drug candidates and approvals?

They are surely coming, but the hurdles are tremendous. Medical cannabis researchers are working in something of a vacuum, with little historical data to draw from due to years of prohibition. The plant itself is a highly complex assembly of active ingredients, or cannabinoids, and the mechanisms of action are not clearly understood. Genetics can vary widely from plant to plant, even within an accepted strain. Overall it seems there is more we don’t know about the plant than what we do. Data, and testing, and trials, and documentation, and interpretation are all sorely lacking.

RYAH Group, Inc. (CSE: RYAH) is here to change all of that with its suite of proprietary smart devices, patented AI-powered data engine, and its huge (and growing) database of medical cannabis use and its effects. RYAH is involved in several international clinical trials and studies, partnering with researchers to make their investigations efficient, productive, and scientifically relevant. RYAH’s data driven solutions are just the sort of medicine that cannabis researchers should be ordering in their quest to legitimize the plant as a pharmaceutical option.

The Intellectual Property

RYAH has been granted what it believes to be the first patent surrounding the use of artificial intelligence in plant-based medicine, including cannabis. Plant-based medicines are often seen as folk remedies, with practitioners relying on anecdotal evidence and a healthy dose of faith in their potential. There are occasional breakthroughs, like the discovery and development of aspirin, but plant-based medicine is in dire need of scientific documentation. And cannabis is perhaps at the head of that particular line right now.

RYAH CEO Greg Wagner discusses IP, including granted and pending patents.

 RYAH also has patents pending for its suite of connected devices – a pen for tinctures, a patch for transdermal applications, and an inhaler for breathable vapors. The devices offer precise and consistent session management for patients, something which can be difficult for people to achieve. They feed data about the volume and usage into an app, which also offers an easy way for users to record their experiences. The app is tied into the larger RYAH database, and the AI behind the system can make recommendations and observations based not only on the individual’s treatment history but on the history of thousands of other patients.

Put it all together and you have a cannabis- and plant-based medicine compendium of knowledge all wrapped up in the RYAH ecosystem. Patients, doctors, cultivators all benefit from the insights made possible by the system. And researchers are increasingly buying into the concept.

Click here to receive an investor presentation and corporate updates

RYAH and Scientific Research

The potential for RYAH’s proprietary system to move cannabis science forward is tantalizing. The more data is gathered, the more insights can be gained and the larger the body of knowledge becomes. RYAH devices are currently being used in a 5-year study in the United Kingdom, expected to cover thousands of patients and comprising one of the largest research projects to date on the efficacy of cannabis and hemp treatments of chronic pain.

Given the size and scale of the study, RYAH has developed a custom software solution, using OAuth API-integration to protect the privacy of the participants in the study, with the goal of enabling a fully integrated, patient feedback and data collection capability. The combination of an IoT controlled device and direct API data integration with the Clinic’s Electronic Health Record (EHR) system is expected to enable scale and mitigate a number of variables associated with data collection and interpretation which are often performed manually for both volume measurement and patient feedback.

RYAH is also involved in a partnership with the University of Milan to develop a standardized dosing measurement system for dry herb. Think about it – how can doctors prescribe cannabis as a treatment without a method for standardizing the dosage? It’s this sort of foundational science that is needed to move cannabis into the medical mainstream, and RYAH’s system is just the type of solution to provide it.

RYAH is also involved in studies in Jersey, the largest of the Channel Islands between England and France. The company’s devices are central to a pilot study in Italy. The company has agreements in France and New Zealand. RYAH also publishes interesting monthly reports on preferences and tendencies based on user data, giving a glimpse of the kind of insights that can be gained.

In the end, RYAH is aggressively moving forward toward its goal of providing, collating, analyzing, and distributing the scientific data and information necessary to normalize cannabis based medical treatments. The opportunity is tremendous, and the need is dire. Those interested in the future of cannabis as a medicine are encouraged to find out more about RYAH Group Inc. (CSE: RYAH) and follow its progress.

Click here to receive an investor presentation and corporate updates

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.